Moleculin Biotech Files 8-K Report
Ticker: MBRX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1659617
Sentiment: neutral
Topics: sec-filing, disclosure
Related Tickers: MBRX
TL;DR
Moleculin Biotech filed an 8-K, likely containing important company updates.
AI Summary
On October 29, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided text snippet.
Why It Matters
This filing indicates Moleculin Biotech is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial or operational details that would indicate high risk.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- October 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 47-4671997 (ein) — I.R.S. Employer Identification No.
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Moleculin Biotech, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 29, 2025.
In which U.S. state is Moleculin Biotech, Inc. incorporated?
Moleculin Biotech, Inc. is incorporated in Delaware.
What is the principal business address of Moleculin Biotech, Inc.?
The principal business address is 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the telephone number provided for Moleculin Biotech, Inc.?
The telephone number is (713) 300-5160.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-10-29 08:35:15
Filing Documents
- mbrx20251028_8k.htm (8-K) — 30KB
- ex_877758.htm (EX-99.1) — 11KB
- logo.jpg (GRAPHIC) — 10KB
- 0001437749-25-032076.txt ( ) — 203KB
- mbrx-20251029.xsd (EX-101.SCH) — 3KB
- mbrx-20251029_def.xml (EX-101.DEF) — 12KB
- mbrx-20251029_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251029_pre.xml (EX-101.PRE) — 12KB
- mbrx20251028_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On October 29, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE," with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity, with a base patent term currently extending until June 2040, subject to extension to account for time required to fulfill requirements for regulatory approval. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 29, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: October 29, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster